FDA Approves Supplemental Application for INREBIC (Fedratinib Hydrochloride)
The FDA has approved a supplemental application for INREBIC, a treatment for myelofibrosis.
Asset / Drug
Drug and asset intelligence for INREBIC with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.